Michael King

Michael King is a seasoned finance and biotechnology professional with extensive experience in leadership roles within the biotech sector. Currently serving as Partner and Head of Finance and Accounting at Miletus Biotechnology, as well as Chief Financial Officer for both Antidote Therapeutics, Inc. and Black Canyon Bio, Michael has been instrumental in various organizations, including Regio Biosciences as a Board Member, focusing on innovative therapies for cardio-metabolic diseases and cancers. In addition to co-founding The BioForge Group, LLC, a biotechnology advisory firm, Michael has held CFO positions at multiple companies, including Scipher Medicine and Primera Therapeutics, emphasizing the application of AI in patient therapy and advancements in gene editing. Michael's career also includes significant roles at Mayflower Bioventures, Adaptive Phage Therapeutics, and consulting for Brown Rudnick LLP. Michael holds an MBA from Columbia Business School and a BA from Wesleyan University.